VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EBMT 2020 | CAR T-cell therapies: selecting patients & associated challenges

Anna Sureda, MD, PhD, of the Catalan Institute of Oncology, Barcelona, Spain, discusses how patients with relapsed/refractory diffuse large B-cell lymphoma are selected for CAR T-cell therapies and associated challenges. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter